Randomized trial of interferon β-1a in chronic inflammatory demyelinating polyradiculoneuropathy

Hadden, Robert D.M.; Sharrack, Basil; Bensa, S; S, Soudain; Hughes, Richard

doi:10.1212/wnl.53.1.57

Cited by 155 publications

(82 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Hadden and colleagues have performed such a study in a randomized double-blinded crossover study of 10 consecutive patients comparing IFN-␤1a versus placebo. 11 One patient improved on IFN-␤, and 2 while receiving placebo. There were no differences in the effect on clinical neurophysiologic measurements.…”

mentioning

confidence: 99%

Type I interferons and chronic inflammatory demyelinating polyneuropathy: Treatment or cause?

Lisak

2000

Muscle Nerve

View full text Add to dashboard Cite

mentioning

confidence: 99%

Type I interferons and chronic inflammatory demyelinating polyneuropathy: Treatment or cause?

Lisak

2000

Muscle Nerve

View full text Add to dashboard Cite

“…This has also been seen in small pilot studies encompassing sensory-motor, or just motor, progressive or relapsing forms of the disease [9][10] . However, our findings and those of other authors [9][10] are at variance with the results of the unique randomized trial of IFN β1a in CIDP 9 which showed no significant difference between IFN β and a placebo in treated patients, albeit over a shorter follow up period. This difference in the follow up periods might explain the variance in results.…”

Section: Discussionmentioning

confidence: 73%

Interferon beta-1a in chronic inflammatory demyelinating polyneuropathy: case report

Villa

Garcea

Egidio

et al. 2004

Arq. Neuro-Psiquiatr.

View full text Add to dashboard Cite

-Chronic inflammatory demyelinating polyneuropathy (CIDP) is an acquired immune-mediated neuropathy. It presents with a course of progression which may be slow and steady or step-wise or relapsing. Sensory ataxic polyneuropathy may be the only clinical manifestation of this disease. Treatment with interferon β1a (INF β1a) has been tried with different results in patients who were refractory to other, more conventional, immunomodulatory therapies. Here we report on a patient who had a relapsing form of pure sensory ataxic CIDP and who failed to respond to intravenous human immunoglobulin. He was put on INF β1a for 3 years. During this period he suffered no relapses while his condition stabilized.KEY WORDS: CIDP, peripheral neuropathy, interferon β (IFN β).Interferon beta en polineuropatía crónica inflamatoria desmienlinizante: caso clínico RESUMEN -La polineuropatía crónica inflamatoria desmielinizante (PCID) es una neuropatía inmuno-mediada, que presenta un curso clínico primariamente progresivo o en forma de recaídas. Las manifestaciones sensoriales pueden ser su unica forma de expresión clínica. El tratamiento con interferon beta 1a (IFN β1a) ha sido ensayado en varias oportunidades, con diferentes respuestas terapéuticas, en pacientes refractarios a las terapias inmunomoduladoras convencionales. Nosotros comunicamos un paciente con una forma ataxica recurrente de PCID, que no respondió al tratamiento con inmunoglobulina endovenosa. Posteriormente fue tratado con IFN β 1 a por tres años. Durante el período de seguimiento no mostró nuevas recaídas y su cuadro neurológico se estabilizó. PALABRAS-CLAVES: neuropatia periferica, interferon beta.In a recent publication, JM Vallat, et al 1 described the results of using intramuscular (IM) Interferon (IFN) β1a to treat patients with chronic inflammatory demyelinating polyneuropathy (CIDP). The investigators found that this medication had an excellent safety and tolerability profile, and that it lead to a statistically significant improvement in the symptoms of neurological disability in some of their patients, those with pure sensory neuropathy were excluded. CIDP is an acquired immune-mediated neuropathy which presents with a course of progression that may be slow and steady or step-wise or relapsing. Sensory ataxic polyneuropathy may be the only clinical manifestation of the disease 2 . Treatments are designed to modulate the abnormal immune response and to suppress ongoing disease activity. Here we report on a patient who had a relapsing form of pure clinical sensory ataxic CIDP and failed to respond to intravenous human immunoglobulin (IVIg) treatment. He was then put on IFN β1a for a period of three years. CASEA 39-year old man presented with a 9-year history of pain, imbalance, and numbness and paresthesias in both feet and hands. The disease presented a relapsing course from the beginning; periods in which the patient´s condition suddenly worsened were followed by others when it stabilized. The patient was suffering one of his relapses when he was firs...

show abstract

“…Azathioprine, cyclophosphamide, cyclosporine, interferon-alpha, interferon-beta, mycophenolate mofetil, and methotrexate have all been reported to be beneficial in CIDP patients not responsive to initial therapies [92][93][94][95][96][97][98][99][100][101][102][103][104][105][106][107][108]. For the most part, these studies were not prospective, randomized, or blinded.…”

Section: Treatmentmentioning

confidence: 99%

“…A negative randomized controlled trial of oral methotrexate 15 mg weekly was reported in CIDP [109]. A recent studied evaluating the effects of intramuscular interferon-beta-1a (Avonex) at low (30 micrograms weekly), intermediate (30 micrograms twice weekly or 60 micrograms weekly) and high dose (60 micrograms twice weekly) on IVIg dose in CIDP did not show a significant benefit [104,105,110]. High dose cyclophosphamide without stem cell rescue can lead to long-term remission with refractory CIDP [97] with improved quality of life [112].…”

Section: Treatmentmentioning

confidence: 99%

Chronic Inflammatory Demyelinating Polyneuropathy

Markvardsen

Harbo²,

Holbech³

et al. 2013

Encyclopedia of Pain

View full text Add to dashboard Cite

Chronic Inflammatory polyneuropathies are an important group of neuromuscular disorders that present chronically and progress over more than 8 weeks, being referred to as chronic inflammatory demyelinating polyneuropathy (CIDP). Despite tremendous progress in elucidating disease pathogenesis, the exact triggering event remains unknown. Our knowledge regarding diagnosis and management of CIDP and its variants continues to expand, resulting in improved opportunities for identification and treatment. Most clinical neurologists will be involved in the management of patients with these disorders, and should be familiar with available therapies for CIDP. We review the distinctive clinical, laboratory, and electro-diagnostic features that aid in diagnosis. We emphasize the importance of clinical patterns that define treatment responsiveness and the most appropriate therapies in order to improve prognosis.

show abstract

Randomized trial of interferon β-1a in chronic inflammatory demyelinating polyradiculoneuropathy

Abstract: This trial shows that IFN-beta is safe but not efficacious in treatment-resistant CIDP.

Cited by 155 publications

References 24 publications

Type I interferons and chronic inflammatory demyelinating polyneuropathy: Treatment or cause?

Type I interferons and chronic inflammatory demyelinating polyneuropathy: Treatment or cause?

Interferon beta-1a in chronic inflammatory demyelinating polyneuropathy: case report

Chronic Inflammatory Demyelinating Polyneuropathy

Contact Info

Product

Resources

About